Industry Research Reports
Home > Reports > Service & Software > Sepsis Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Sepsis Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
Industry: Service & Software
Published Date: 2026-07-15
Pages: 103 Pages
Report ld: 6973826
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Sepsis Therapeutics Market Size(US$)
CAGR 2026-2032
6.7%
Market Size,2032
USD 6,352
Million
Market Snapshot
Market Size in 2026 (Value)
US$ 4,305 million
Market Forecast in 2032(Value)
US$ 6,352 million
CAGR
6.7%
Years Considered
2021-2032
Base Year
2026
Forecast Period
2026-2032
Source: Secondary research, interviews with experts, and QYResearch analysis
The global market for Sepsis Therapeutics was estimated to be worth US$ 4060 million in 2025 and is projected to reach US$ 6352 million, growing at a CAGR of 6.7% from 2026 to 2032.
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report provides a comprehensive view of the global market for Sepsis Therapeutics, covering total sales revenue, the market share and ranking of key companies, along with analyses by region & country, by Type, and by Application.
The Sepsis Therapeutics market size, estimations, and forecasts are presented in terms of sales revenue ($ millions), with 2025 as the base year and historical and forecast data from 2021 to 2032. The report combines quantitative and qualitative analysis to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current marketplace, and make informed business decisions regarding Sepsis Therapeutics.
MARKET SEGMENTATION
By Company
- Agennix
- AstraZeneca
- Atox Bio
- CytoGenix
- Eli Lilly
- Endacea
- NexBio
- Medinox
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Aminoglycosides
- Colony Stimulating Factors
- Second Generation Cephalosporins
- Third Generation Cephalosporins
- Glycopeptide Antibiotics
- Inhaled Intifectives
- Others
Segment by Application
- Hospitals
- Clinics
- Other
CHAPTER OUTLINE
Chapter 1: Introduces the scope of the report and the global market size (value). It also summarizes market dynamics and recent developments; identifies key drivers and restraints; outlines challenges and risks for players; reviews relevant industry policies.
Chapter 2: Provides a detailed analysis of the Sepsis Therapeutics companies' competitive landscape—including revenue shares, recent development plans, and mergers and acquisitions (M&A).
Chapter 3: Analyzes market segmentation by Type, presenting the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 4: Analyzes market segmentation by Application, presenting the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 5: Presents Sepsis Therapeutics revenue at the regional level. It offers a quantitative assessment of market size and growth potential by region and summarizes market development, future prospects, addressable space, and country-level market size worldwide.
Chapter 6: Presents Sepsis Therapeutics revenue at the country level. It provides segmented data by Type and by Application for each country/region.
Chapter 7: Profiles key players, detailing the main companies' product revenue, gross margin, product portfolios, recent developments, etc.
Chapter 8: Analysis of Value Chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Market Overview
1.1 Sepsis Therapeutics Product Introduction
1.2 Global Sepsis Therapeutics Market Size Forecast (2021–2032)
1.3 Sepsis Therapeutics Market Trends & Drivers
1.3.1 Sepsis Therapeutics Industry Trends
1.3.2 Sepsis Therapeutics Market Drivers & Opportunities
1.3.3 Sepsis Therapeutics Market Challenges
1.3.4 Sepsis Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Sepsis Therapeutics Players Revenue Ranking (2025)
2.2 Global Sepsis Therapeutics Revenue by Company (2021–2026)
2.3 Key Companies’ R&D and Operations Footprint and Headquarters
2.4 Key Companies Sepsis Therapeutics Product Offerings
2.5 Key Companies General Availability (GA) Timeline for Sepsis Therapeutics
2.6 Sepsis Therapeutics Market Competitive Analysis
2.6.1 Sepsis Therapeutics Market Concentration Rate (2021–2026)
2.6.2 Top 5 and Top 10 Global Companies by Sepsis Therapeutics Revenue in 2025
2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Sepsis Therapeutics revenue, 2025
2.7 Mergers & Acquisitions and Expansion
3 Segmentation Sepsis Therapeutics Market Classification
3.1 Introduction by Type
3.1.1 Aminoglycosides
3.1.2 Colony Stimulating Factors
3.1.3 Second Generation Cephalosporins
3.1.4 Third Generation Cephalosporins
3.1.5 Glycopeptide Antibiotics
3.1.6 Inhaled Intifectives
3.1.7 Others
3.1.8 Global Sepsis Therapeutics Sales Value by Type
3.1.8.1 Global Sepsis Therapeutics Sales Value by Type (2021 vs 2025 vs 2032)
3.1.8.2 Global Sepsis Therapeutics Sales Value, by Type (2021–2032)
3.1.8.3 Global Sepsis Therapeutics Sales Value, by Type (%), 2021–2032
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Sepsis Therapeutics Sales Value by Application
4.2.1 Global Sepsis Therapeutics Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Sepsis Therapeutics Sales Value by Application (2021–2032)
4.2.3 Global Sepsis Therapeutics Sales Value by Application (%), 2021–2032
5 Segmentation by Region
5.1 Global Sepsis Therapeutics Sales Value by Region
5.1.1 Global Sepsis Therapeutics Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Sepsis Therapeutics Sales Value by Region (2021–2026)
5.1.3 Global Sepsis Therapeutics Sales Value by Region (2027–2032)
5.1.4 Global Sepsis Therapeutics Sales Value by Region (%), 2021–2032
5.2 North America
5.2.1 North America Sepsis Therapeutics Sales Value, 2021–2032
5.2.2 North America Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
5.3 Europe
5.3.1 Europe Sepsis Therapeutics Sales Value, 2021–2032
5.3.2 Europe Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
5.4 Asia Pacific
5.4.1 Asia Pacific Sepsis Therapeutics Sales Value, 2021–2032
5.4.2 Asia Pacific Sepsis Therapeutics Sales Value by Subregion (%), 2025 vs 2032
5.5 South America
5.5.1 South America Sepsis Therapeutics Sales Value, 2021–2032
5.5.2 South America Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
5.6 Middle East & Africa
5.6.1 Middle East & Africa Sepsis Therapeutics Sales Value, 2021–2032
5.6.2 Middle East & Africa Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Sepsis Therapeutics Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Sepsis Therapeutics Sales Value, 2021–2032
6.3 United States
6.3.1 United States Sepsis Therapeutics Sales Value, 2021–2032
6.3.2 United States Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Sepsis Therapeutics Sales Value, 2021–2032
6.4.2 Europe Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Sepsis Therapeutics Sales Value, 2021–2032
6.5.2 China Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.5.3 China Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Sepsis Therapeutics Sales Value, 2021–2032
6.6.2 Japan Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Sepsis Therapeutics Sales Value, 2021–2032
6.7.2 South Korea Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Sepsis Therapeutics Sales Value, 2021–2032
6.8.2 Southeast Asia Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Sepsis Therapeutics Sales Value, 2021–2032
6.9.2 India Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
6.9.3 India Sepsis Therapeutics Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Agennix
7.1.1 Agennix Profile
7.1.2 Agennix Main Business
7.1.3 Agennix Sepsis Therapeutics Products, Services, and Solutions
7.1.4 Agennix Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.1.5 Agennix Recent Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Profile
7.2.2 AstraZeneca Main Business
7.2.3 AstraZeneca Sepsis Therapeutics Products, Services, and Solutions
7.2.4 AstraZeneca Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.2.5 AstraZeneca Recent Developments
7.3 Atox Bio
7.3.1 Atox Bio Profile
7.3.2 Atox Bio Main Business
7.3.3 Atox Bio Sepsis Therapeutics Products, Services, and Solutions
7.3.4 Atox Bio Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.3.5 Atox Bio Recent Developments
7.4 CytoGenix
7.4.1 CytoGenix Profile
7.4.2 CytoGenix Main Business
7.4.3 CytoGenix Sepsis Therapeutics Products, Services, and Solutions
7.4.4 CytoGenix Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.4.5 CytoGenix Recent Developments
7.5 Eli Lilly
7.5.1 Eli Lilly Profile
7.5.2 Eli Lilly Main Business
7.5.3 Eli Lilly Sepsis Therapeutics Products, Services, and Solutions
7.5.4 Eli Lilly Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.5.5 Eli Lilly Recent Developments
7.6 Endacea
7.6.1 Endacea Profile
7.6.2 Endacea Main Business
7.6.3 Endacea Sepsis Therapeutics Products, Services, and Solutions
7.6.4 Endacea Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.6.5 Endacea Recent Developments
7.7 NexBio
7.7.1 NexBio Profile
7.7.2 NexBio Main Business
7.7.3 NexBio Sepsis Therapeutics Products, Services, and Solutions
7.7.4 NexBio Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.7.5 NexBio Recent Developments
7.8 Medinox
7.8.1 Medinox Profile
7.8.2 Medinox Main Business
7.8.3 Medinox Sepsis Therapeutics Products, Services, and Solutions
7.8.4 Medinox Sepsis Therapeutics Revenue (US$ Million), 2021–2026
7.8.5 Medinox Recent Developments
8 Industry Chain Analysis
8.1 Sepsis Therapeutics Value Chain
8.2 Sepsis Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Cost Structure
8.3 Midstream Analysis
8.4 Downstream (Customer) Analysis
8.5 Sales Model and Sales Channelss
8.5.1 Sepsis Therapeutics Sales Model
8.5.2 Sales Channels
8.5.3 Sepsis Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Sepsis Therapeutics Market Trends
Table 2. Sepsis Therapeutics Market Drivers & Opportunities
Table 3. Sepsis Therapeutics Market Challenges
Table 4. Sepsis Therapeutics Market Restraints
Table 5. Global Sepsis Therapeutics Revenue by Company (US$ Million), 2021–2026
Table 6. Global Sepsis Therapeutics Revenue Market Share by Company (2021–2026)
Table 7. Key Companies’ R&D and Operations Footprint and Headquarters
Table 8. Key Companies Sepsis Therapeutics Product Type
Table 9. Key Companies General Availability (GA) Timeline for Sepsis Therapeutics
Table 10. Global Sepsis Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Sepsis Therapeutics revenue, 2025
Table 12. Mergers & Acquisitions and Expansion Plans
Table 13. Global Sepsis Therapeutics Sales Value by Type: 2021 vs 2025 vs 2032 (US$ Million)
Table 14. Global Sepsis Therapeutics Sales Value by Type (US$ Million), 2021–2026
Table 15. Global Sepsis Therapeutics Sales Value by Type (US$ Million), 2027–2032
Table 16. Global Sepsis Therapeutics Sales Market Share in Value by Type (2021–2026)
Table 17. Global Sepsis Therapeutics Sales Market Share in Value by Type (2027–2032)
Table 18. Global Sepsis Therapeutics Sales Value by Application: 2021 vs 2025 vs 2032 (US$ Million)
Table 19. Global Sepsis Therapeutics Sales Value by Application (US$ Million), 2021–2026
Table 20. Global Sepsis Therapeutics Sales Value by Application (US$ Million), 2027–2032
Table 21. Global Sepsis Therapeutics Sales Market Share in Value by Application (2021–2026)
Table 22. Global Sepsis Therapeutics Sales Market Share in Value by Application (2027–2032)
Table 23. Global Sepsis Therapeutics Sales Value by Region, (US$ Million), 2021 vs 2025 vs 2032
Table 24. Global Sepsis Therapeutics Sales Value by Region (US$ Million), 2021–2026
Table 25. Global Sepsis Therapeutics Sales Value by Region (US$ Million), 2027–2032
Table 26. Global Sepsis Therapeutics Sales Value by Region (%), 2021–2026
Table 27. Global Sepsis Therapeutics Sales Value by Region (%), 2027–2032
Table 28. Key Countries/Regions Sepsis Therapeutics Sales Value Growth Trends, (US$ Million): 2021 vs 2025 vs 2032
Table 29. Key Countries/Regions Sepsis Therapeutics Sales Value, (US$ Million), 2021–2026
Table 30. Key Countries/Regions Sepsis Therapeutics Sales Value, (US$ Million), 2027–2032
Table 31. Agennix Basic Information List
Table 32. Agennix Description and Business Overview
Table 33. Agennix Sepsis Therapeutics Products, Services, and Solutions
Table 34. Revenue (US$ Million) in Sepsis Therapeutics Business of Agennix (2021–2026)
Table 35. Agennix Recent Developments
Table 36. AstraZeneca Basic Information List
Table 37. AstraZeneca Description and Business Overview
Table 38. AstraZeneca Sepsis Therapeutics Products, Services, and Solutions
Table 39. Revenue (US$ Million) in Sepsis Therapeutics Business of AstraZeneca (2021–2026)
Table 40. AstraZeneca Recent Developments
Table 41. Atox Bio Basic Information List
Table 42. Atox Bio Description and Business Overview
Table 43. Atox Bio Sepsis Therapeutics Products, Services, and Solutions
Table 44. Revenue (US$ Million) in Sepsis Therapeutics Business of Atox Bio (2021–2026)
Table 45. Atox Bio Recent Developments
Table 46. CytoGenix Basic Information List
Table 47. CytoGenix Description and Business Overview
Table 48. CytoGenix Sepsis Therapeutics Products, Services, and Solutions
Table 49. Revenue (US$ Million) in Sepsis Therapeutics Business of CytoGenix (2021–2026)
Table 50. CytoGenix Recent Developments
Table 51. Eli Lilly Basic Information List
Table 52. Eli Lilly Description and Business Overview
Table 53. Eli Lilly Sepsis Therapeutics Products, Services, and Solutions
Table 54. Revenue (US$ Million) in Sepsis Therapeutics Business of Eli Lilly (2021–2026)
Table 55. Eli Lilly Recent Developments
Table 56. Endacea Basic Information List
Table 57. Endacea Description and Business Overview
Table 58. Endacea Sepsis Therapeutics Products, Services, and Solutions
Table 59. Revenue (US$ Million) in Sepsis Therapeutics Business of Endacea (2021–2026)
Table 60. Endacea Recent Developments
Table 61. NexBio Basic Information List
Table 62. NexBio Description and Business Overview
Table 63. NexBio Sepsis Therapeutics Products, Services, and Solutions
Table 64. Revenue (US$ Million) in Sepsis Therapeutics Business of NexBio (2021–2026)
Table 65. NexBio Recent Developments
Table 66. Medinox Basic Information List
Table 67. Medinox Description and Business Overview
Table 68. Medinox Sepsis Therapeutics Products, Services, and Solutions
Table 69. Revenue (US$ Million) in Sepsis Therapeutics Business of Medinox (2021–2026)
Table 70. Medinox Recent Developments
Table 71. Revenue (US$ Million) in Sepsis Therapeutics Business of Company 40 (2021–2026)
Table 72. Company 40 Recent Developments
Table 73. Key Raw Materials Lists
Table 74. Key Suppliers of Raw Materials Lists
Table 75. Sepsis Therapeutics Downstream Customers
Table 76. Sepsis Therapeutics Distributors List
Table 77. Research Programs/Design for This Report
Table 78. Key Data Information from Secondary Sources
Table 79. Key Data Information from Primary Sources
List of Figures
Figure 1. Sepsis Therapeutics Product Picture
Figure 2. Global Sepsis Therapeutics Sales Value, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Global Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 4. Sepsis Therapeutics Report Years Considered
Figure 5. Global Sepsis Therapeutics Players Revenue Ranking (US$ Million), 2025
Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Sepsis Therapeutics Revenue in 2025
Figure 7. Sepsis Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 8. Aminoglycosides Picture
Figure 9. Colony Stimulating Factors Picture
Figure 10. Second Generation Cephalosporins Picture
Figure 11. Third Generation Cephalosporins Picture
Figure 12. Glycopeptide Antibiotics Picture
Figure 13. Inhaled Intifectives Picture
Figure 14. Others Picture
Figure 15. Global Sepsis Therapeutics Sales Value by Type (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Sepsis Therapeutics Sales Value Market Share by Type, 2025 & 2032
Figure 17. Product Picture of Hospitals
Figure 18. Product Picture of Clinics
Figure 19. Product Picture of Other
Figure 20. Global Sepsis Therapeutics Sales Value by Application (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Sepsis Therapeutics Sales Value Market Share by Application, 2025 & 2032
Figure 22. North America Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 23. North America Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 24. Europe Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 25. Europe Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 26. Asia Pacific Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 27. Asia Pacific Sepsis Therapeutics Sales Value by Subregion (%), 2025 vs 2032
Figure 28. South America Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 29. South America Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 30. Middle East & Africa Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 31. Middle East & Africa Sepsis Therapeutics Sales Value by Country (%), 2025 vs 2032
Figure 32. Key Countries/Regions Sepsis Therapeutics Sales Value (%), 2021–2032
Figure 33. United States Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 34. United States Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 35. United States Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 36. Europe Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 37. Europe Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 38. Europe Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 39. China Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 40. China Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 41. China Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 42. Japan Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 43. Japan Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 44. Japan Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 45. South Korea Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 46. South Korea Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 47. South Korea Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 48. Southeast Asia Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 49. Southeast Asia Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 50. Southeast Asia Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 51. India Sepsis Therapeutics Sales Value (US$ Million), 2021–2032
Figure 52. India Sepsis Therapeutics Sales Value by Type (%), 2025 vs 2032
Figure 53. India Sepsis Therapeutics Sales Value by Application (%), 2025 vs 2032
Figure 54. Sepsis Therapeutics Value Chain
Figure 55. Sepsis Therapeutics Cost Structure
Figure 56. Channels of Distribution (Direct Sales, and Distribution)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 6.7% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
Which companies rank high in the global Sepsis Therapeutics market?
What was the global market size of Sepsis Therapeutics in 2026?
What was the global market size of Sepsis Therapeutics in 2032?
What is the annual compound growth rate of the global Sepsis Therapeutics market size from 2026 to 2032?
Related Reports
Global Sepsis Therapeutics Market Research Report 2026
The global Sepsis Therapeutics market was valued at US$ 4060 million in 2025 and is anticipated to reach US$ 6352 million by 2032, at a CAGR of 6.7% from 2026 to 2032.
Published Date: 2026-04-28
Pages: 107
USD 2900.00
(Single User License)
Global Sepsis Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Sepsis Therapeutics market size was US$ 3829 million in 2024 and is forecast to a readjusted size of US$ 5991 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 77
USD 4250.00
(Single User License)
Global Sepsis Therapeutics Market Research Report 2025
The global market for Sepsis Therapeutics was valued at US$ 3829 million in the year 2024 and is projected to reach a revised size of US$ 5991 million by 2031, growing at a CAGR of 6.7% during the forecast period.
Published Date: 2025-02-27
Pages: 72
USD 2900.00
(Single User License)
Sepsis Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Sepsis Therapeutics was estimated to be worth US$ 3829 million in 2024 and is forecast to a readjusted size of US$ 5991 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 87
USD 3950.00
(Single User License)
Global Sepsis Therapeutics Market Insights, Forecast to 2030
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published Date: 2024-04-25
Pages: 93
USD 4900.00
(Single User License)
Sepsis Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published Date: 2024-01-24
Pages: 80
USD 3950.00
(Single User License)
Global Sepsis Therapeutics Market Research Report 2024
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published Date: 2024-01-11
Pages: 79
USD 2900.00
(Single User License)
Global Sepsis Therapeutics Market Research Report 2026
The global Sepsis Therapeutics market was valued at US$ 4060 million in 2025 and is anticipated to reach US$ 6352 million by 2032, at a CAGR of 6.7% from 2026 to 2032.
Published: 2026-04-28
Pages: 107
USD 2900.00 (Single User License)Global Sepsis Therapeutics Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Sepsis Therapeutics market size was US$ 3829 million in 2024 and is forecast to a readjusted size of US$ 5991 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 77
USD 4250.00 (Single User License)Global Sepsis Therapeutics Market Research Report 2025
The global market for Sepsis Therapeutics was valued at US$ 3829 million in the year 2024 and is projected to reach a revised size of US$ 5991 million by 2031, growing at a CAGR of 6.7% during the forecast period.
Published: 2025-02-27
Pages: 72
USD 2900.00 (Single User License)Sepsis Therapeutics- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Sepsis Therapeutics was estimated to be worth US$ 3829 million in 2024 and is forecast to a readjusted size of US$ 5991 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 87
USD 3950.00 (Single User License)Global Sepsis Therapeutics Market Insights, Forecast to 2030
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published: 2024-04-25
Pages: 93
USD 4900.00 (Single User License)Sepsis Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published: 2024-01-24
Pages: 80
USD 3950.00 (Single User License)Global Sepsis Therapeutics Market Research Report 2024
Sepsis is usually treated with intravenous fluids and antibiotics. Typically, antibiotics are given as soon as possible. Often, ongoing care is performed in an intensive care unit. If fluid replacement is not enough to maintain blood pressure, medications that raise blood pressure may be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide treatment, a central venous catheter and an arterial catheter may be placed for access to the bloodstream. Other measurements such as cardiac output and superior vena cava oxygen saturation may be used. People with sepsis need preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent such interventions. Some might benefit from tight control of blood sugar levels with insulin. The use of corticosteroids is controversial, with some reviews finding benefit, and others not.
Published: 2024-01-11
Pages: 79
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 3950.00
USD 5925.00
USD 7900.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now